• RedHill Biopharma increased the maximum aggregate amount of American depositary shares it may sell under its at-the-market offering program.
• The ADS may be issued from time to time under the equity distribution agreement with H.C. Wainwright, originally signed Feb. 3, 2025.
• Each ADS represents 10,000 ordinary shares with par value NIS 0.01 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-003351), on June 29, 2026, and is solely responsible for the information contained therein.